Sei sulla pagina 1di 30

Key Factors to Design Quality Stability Program for Drug Product and API

Kim Huynh-Ba PHARMALYTIK

Pharmalytik

OVERVIEW
Stability role in the drug development process Review cGMP and ICH stability requirements Develop Global Stability Protocols Design stability program by Phases of Development Presentation will focus on small molecules.

Pharmalytik

AAPS_0409: 2

Goals of Stability Testing


ACTIVE PHARMACEUTICAL INGREDIENT (API)
To establish a retest date for API Data to support setting API specifications Data to support submission of drug product

PHARMACEUTICAL DRUG PRODUCT


Data to support setting specifications for drug product To establish a shelf-life for the commercial product

Pharmalytik

AAPS_0409: 3

Critical Role of Drug Stability


Quality must be established for identity, strength, quality and purity (CFR 211.137) to assure Safety and Efficacy during its shelf life when stored under the intended labeled condition. Safety and Efficacy of drug product are established during development via clinical studies If drug product stability changes beyond established acceptance criteria, established safety and efficacy are no longer applicable. Change of Drug Stability would risk patient safety
Quality of finished products decrease Potential sub-potent or over-dose products Potential toxic unknown impurities

Potential new degradants of unknown toxicity

Uncontrolled process product investigation product recalls cGMP violations consent decree criminal prosecution
Pharmalytik
AAPS_0409: 4

Drug Product Stability


Stability characteristics of API or Drug Product is a critical quality attribute of pharmaceutical product Stability Studies are used to:
Establish how product changes over time under critical environmental factors (temperature, heat and light) Determine appropriate product specifications Select marketing container closure system Determine appropriate storage conditions Justification of expiry of commercial product Provide necessary medical supplies

Pharmalytik

AAPS_0409: 5

Factors affecting Drug Stability


Stability of the API from storage Interaction between the API and excipient Form. Dev. Selection of dosage form Manufacturing process of drug product Selection of container closure packaging system Effect of storage (temperature, humidity and light) Selection of marketing image Handling of the finished products
Pharmalytik
AAPS_0409: 6

DRUG DEVELOPMENT PROCESS


Excipients Drug Product Stability Excipient compatibility Formulation interaction

FORMULATION DEVELOPMENT

PACKAGING SELECTION

API Stability Process impurity

Pharmalytik

Packaging interaction Storage conditions Storage configuration

AAPS_0409: 7

Drug Development Process


Discovery Pre-clinical Years 3.5
Lab and Animal Studies

Phase I 1.5

Clinical Trials Phase III Phase II 2 3.5


1,000 - 5,000 patient volunteers Confirm effectiveness, monitor adverse reactions from long-term use

Phase IV 1.5 Review and Approval 1 File NDA


AAPS_0409: 8

Test Population

20 - 100 100 - 500 patient healthy volunteers volunteers Evaluate Effectiveness, look for side effects

Purpose

Safety, biological Safety and activity and formulation Dosage

Additional postmarketing testing required by FDA

Success Rate
Pharmalytik

5,000 evaluated File IND

5 enter clinical trials

Purpose of Stability Testing


The purpose of stability testing is to provide evidence on how the quality of a drug substance or drug product varies with time under the influence of a variety of environmental factors such as temperature, humidity and light. Stability testing permits the establishment of recommended storage conditions, retest periods, and shelf-lives.
ICH harmonized Tripartite Guideline for Stability Testing of New Drug Substances and Products [ICH Q1A] AAPS_0409: 9

Pharmalytik

211.166 Stability Testing


Stability program must be written and followed: (a) used in determining appropriate storage conditions and expiration date. Written program must include: Sample size and test intervals, Storage conditions for samples, Reliable, meaningful, and specific test methods, Testing of drug product in marketed container, Testing of drug product for reconstitution at dispensing time and reconstituted time.
Pharmalytik
AAPS_0409: 10

211.166 Stability Testing


(b) An adequate number of batches must be tested to determine an appropriate expiration date. A record of such data must be maintained. Accelerated studies, combined with basic stability information on the components, drug products, and container-closure system, may be used to support tentative expiration dates. Full shelf-life studies, if not available, are being conducted.
Pharmalytik
AAPS_0409: 11

211.137 EXPIRATION DATING


(a) To assure that a drug product meets applicable standards of identity, strength, quality, and purity at the time of use, it shall bear an expiration date determined by appropriate stability testing described in Sec. 211.166. (b) Expiration dates shall be related to any storage conditions stated on the labeling, as determined by stability studies described in Sec. 211.166.

Pharmalytik

AAPS_0409: 12

International Conference on Harmonization (ICH)


Purpose: To provide a forum for dialogue between Health Authorities and Industry on the disparities with respect to requirements of US, Europe and Japan (Zone 1 & 2) Goal: To develop guidelines that are acceptable for regulatory review by US, Europe and Japan ICH Steering Committee: 6 Parties PhRMa, FDA, EFPIA, EU, MHLW, JPMA and IFPMA (non voting member) Official Observers: Canada, WHO, EFTA Interested Parties: Pharmacopeia, IGPA, WSMI
Pharmalytik
AAPS_0409: 13

5 Major Steps in ICH Process


Harmonizing Stability Storage Conditions
STEP 1 STEP 2 STEP 3 STEP 4 STEP 5

Consensus Building By EWG

Regulatory Consultation Consensus Agreed by 6 parties Adoption Of ICH Guideline

Implementation

Handbook of Stability Testing in Pharmaceutical Development: Regulations, Methodologies and Best Practices K. Huynh-Ba (ed.), Springer, November 2008, Chapter 2.

Pharmalytik

AAPS_0409: 14

ICH Guidances
M4: Common Technical Document (CTD) for the Registration of Pharmaceuticals for Human Use (CTD) (October 2001); Q1A(R2): Stability Testing of New Drug Substances and Products (November 2003); Q1B Photostability Testing of New Drug Substances and Product (November 1996); Q1C Stability Testing of New Dosage Forms (May 1997); Q1D Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products (January 2003); Q1E Evaluation of Stability Data (June 2004); Q1F Stability Data Package for Registration Applications in Climatic Zones III and IV, Revision 1 (July 2004); Ref: US FDA, Guidance for Industry on Chemistry, Manufacturing, and Controls Informations; Withdrawal and Revision of Seven Guidances, Federal Register 71 (105), 31194-31195 (June 1, 2006) DOCID: fr01jn06-73

Pharmalytik

AAPS_0409: 15

ICH Storage Conditions


Intended Storage Condition Stability Studies Long Term Room Temperature Intermediate* Accelerated Long Term Refrigerated Accelerated Freezer Long Term 25 C/60%RH - 20 C/ ambient 6 months 12 months Study Condition 25 C/60%RH 30 C/65%RH 40 C/75%RH 5 C/ ambient Submission Requirement 12 months 6 months 6 months 12 months

* Significant change Pharmalytik


AAPS_0409: 16

Significant Change
API Significant change is defined as failure to meet the specification. 1. A 5 percent potency change from the initial assay value; 2. Any specified degradant exceeding its acceptance criteria Drug Product 3. Failure to meet acceptance criteria for appearance and physical properties (e.g., color, phase separation, resuspendibility, delivery per actuation, caking, hardness); and as appropriate to the product type; 4. The pH exceeding its acceptance criteria; and 5. Dissolution exceeding the acceptance criteria for 12 dosage units.
Pharmalytik
AAPS_0409: 17

Global Climatic Zones


Zone I: Temperate less than 20oC
e.g. Germany, Russia, Canada

Zone II: Sub-tropical with possible high humidity


averaging 20.5-24oC e.g. France, Peru, Australia, USA

Zone III: hot and dry


e.g. Botswana, Chad, Syria, Iraq

Zone IV: hot and humid


averaging more than 24oC e.g. Taiwan, Singapore, India, parts of South America
Pharmalytik
AAPS_0409: 18

WHO Meetings
WHO Draft Guidance Nov 2003
Zone IV --long term testing at 30C/65% RH

Association of Southeast Asian Nations (A.S.E.A.N.) Cambodia, Brunei, Indonesia, Laos, Malaysia, Philippines, Singapore, Thailand, Vietnam. WHO Decision - 2005 Split current Climatic Zone IV into
IVA long term testing at 30C/65% RH IVB long term testing at 30C/75% RH Members decide of which condition
Pharmalytik
AAPS_0409: 19

Why?
Storage conditions listed in ICH and WHO guidelines based on average values in 23 cities Conditions of other cities are more stressful in term of temperature and humidity not representative Poor storage conditions, especially in rural areas. Average temperature and humidity is 27C and 79%RH Recommend long term storage to be 30C/75% RH, and 40 C/75% RH for accelerated condition June 2004 This condition is also preferred by some South American countries such as Brazil ASEAN prefers more stressful condition than 30C/65% RH. Chosen condition reflects extremes rather than average as ICH.
Pharmalytik
AAPS_0409: 20

Typical Global Stability Protocol


Cond. 25 C 60%RH 30 C 65%RH (30 C 75%RH) 40 C 75%RH 50 C Photo 5C (X) H O L D TZ X (X) (X) X 1mo 2mo 3mo X X X X X 6mo X X X X 9mo X X X 12mo X X X 18mo X X X 24mo X X X 36mo X X X

Handbook of Stability Testing in Pharmaceutical Development: Regulations, Methodologies and Best Practices, K. Huynh-Ba (ed.), Springer, November 2008

Pharmalytik

AAPS_0409: 21

Global Stability Summary


Registration Storage Conditions
Long-term (ICH) Intermediate (ICH) Long-term (WHO) Long-term (ASEAN & Brazil) Accelerated (ICH & WHO) 25C/60%RH 30C/65%RH (HOLD) 30C/65%RH 30C/75%RH 40C/75%RH Photostability Freeze-thaw Thermal cycling

Other stress conditions


30C/90%RH 50C 60C

Ideally, a global stability program for all registrations of a drug product Pharmalytik

AAPS_0409: 22

Environmental Chambers
Two basic types: Reach-In and Walk-In Reach-in chambers can be a self-contained units with good profile control, but have limited space. Walk-in chambers have more storage space but are more difficult to control and validate
All chamber units must have temperature and humidity control over a defined range with suitable tolerances to meet ICH specifications. Must have continuous monitoring of parameters to allow documentation of chamber integrity at all times.
Pharmalytik
AAPS_0409: 23

Key Factors of Stability Chambers


Chamber should be calibrated to appropriate technical specs. Chamber should be validated with profiling matrix. Temperature and humidity should be recorded continuously. SOPs for operation of chamber should be prepared and controlled. Units should have logbooks for maintenance and repairs. Units should have secured access to prevent tampering. If electronic information is collected, the system should be compliant with 21CFR11 requirements. Alarm and backup systems should be in place to detect power failures and prevent station from crashing. Procedures should be in place for man-made or natural disasters.

Pharmalytik

AAPS_0409: 24

Selection of batches
API
Selection of Batches Manufacturing Process Acceptance Criteria Container Closure Stability Commitment
Pharmalytik

DRUG PRODUCT
3 batches/strength (2 pilot + 1 lab scale)

3 batches (pilot scale)

Representative of Commercial Production Similar to those used in pre-clinical and clinical studies Same to proposed commercial packaging Must commit to put up 3 production batches with same protocol
AAPS_0409: 25

Key Factors of Q1A(R2)


Must use Validated Stability-Indicating analytical methods Methods must cover physical, chemical, biological and microbiological attributes Studies evaluated under thermal and elevated humidity to cover storage, shipment and subsequent use Accelerated and intermediate used to evaluate impact of short-term excursions. Acceptance criteria should include individual and total upper limits for impurities and degradation products No formal statistical analysis is needed if data show little degradation or variability.
Pharmalytik
AAPS_0409: 26

Shelf-Life Projection
The shelf life is the time point where the 95 % confidence interval for interval the regression line crosses the specification.

Pharmalytik

AAPS_0409: 27

Example 2 - One Batch

Pharmalytik

AAPS_0409: 28

Q1E examples

Pharmalytik

AAPS_0409: 29

Shelf-Life Projection-Multiple batches

Pharmalytik

AAPS_0409: 30

Multiple Batches

Pharmalytik

AAPS_0409: 31

Example - Multiple Batches

Pharmalytik

AAPS_0409: 32

Important Dates of Stability Study


Packaging Date Manufacturing Date

Study Start Date Stability Pull Dates

Expiration Date (Study End Date)

Release Date

Batch Manufactured Release Testing

TZ Testing Stability Scheduled Testing

Drug Product Expiry

Stability Testing in Pharmaceutical Development Handbook: Regulations, Methodologies and Best Practices, K.Huynh-Ba, ed., Nov. 2008.

Pharmalytik

AAPS_0409: 33

Considerations for Generics


OGD believes that stability of drug products is best ensured through Quality by Design (QbD) OGDs Question-based Review (QbR) covers quality by design Include stress testing studies or studies incorporated by DMF reference Stability data is still needed to verify quality product quality and establish a shelf-life consistent with that quality Three batches if it is a complex drug product
Study Long-term Accelerated Storage Condition 25C 2C 60% RH 5% RH 40C 2C 75% RH 5% RH Minimum data at submission Additional data as it becomes available 3 months (0, 1, 2, and 3 months) # of Batches One batch One batch

Pharmalytik

AAPS_0409: 34

Considerations for OTC


Draft guidelines from CHPA available in March 2004 for OTC Drug Products in the U.S. (that are not regulated by an NDA/ANDA). Draft guidelines for changes to OTCs (major, moderate, minor) Reduce some stability burden especially for those with extensive experience and history and excellent safety profiles.
ICH Q1A(R2) (for NCEs) # Batches Batch Size 3 2 at 1/10th scale 3rd may be smaller Testing Intervals LT 8 points ACC 4 points Photostability Expiry Dating At least 1 Batch Long Term & Accelerated 12 Months Data CHPA SWG Guideline (for OTCs) At least 1 1/10th Scale (justification needed for smaller size) LT 5 points Accel at least 3 pts May be Accelerated 3 Months Data AAPS_0409: 35

Pharmalytik

Design Stability Program by Phases

Pharmalytik

Design Program by Phases


Stability Program varies depending on the phase and clinical study it supports Stability Study Goals...
Identify problems early Know your product Minimize repeat study Identify critical control attributes i.e., Particle size

Develop a stable commercial product Maintain database--stability informatics Establish systems to cycle back learning Develop stability strategies to expedite product development
AAPS_0409: 37

Pharmalytik

Pre-Phase I strategies...
Identify problems early
Test drug substance stability at: 25 C (sealed glass ampul (SGA)) 25 C/85%RH (open container) 40 C (SGA) 40 C/75%RH (open container) 40 C plus 5% water 60 C (SGA) 60 C plus 5% water (w/w) ICH photostability twice ICH photostability
Pharmalytik
AAPS_0409: 38

Early Phase strategies...


Know your product
Aqueous solubility pH-solubility profile Solubility in various solvents used in AMES Hygroscopicity Crystallinity (XRPD, Polarized light microscopy) Thermal Analysis (DSC, TGA) Excipient compatibility studies (start early Phase I)

Pharmalytik

AAPS_0409: 39

Phase I Strategies...
Goals Reduce cycle time Get into man fast Determine pK and tolerability Pick the best in a cluster nomination Select formulation to minimize development time Standard solid dosage formulations Powder in a bottle (PIB) Liquid filled gel caps Begin work on Phase II dosage form--solid, liquid, etc. Understand the stability of your product
Pharmalytik
AAPS_0409: 40

Powder in a Bottle (PIB)


Drug substance in a bottle Constitute at site as solution or suspension prior to oral administration to subjects Constitute with commercially available Vehicles--Simple Syrup; sodium lauryl sulfate (SLS), etc. Advantages: Uses same methods as used for drug substance Uses stability of drug substance to support product and establish retest date Demonstrates stability in solution and no interference from excipients Gives formulators opportunity to develop Phase II dosage form in parallel
Pharmalytik
AAPS_0409: 41

Phase I/II Stability Protocol


Conditions 25 C 60%RH (30 C 65%RH)** 40 C 75%RH 40 C/75%RH (Exposed) TZ X (X) X X 1mo 2mo (X) (X) (X) 3mo X X X 6mo X X X 9mo X X 12mo X X End of Study X X

**30 C/65%RH if clinical study is done in Zone III/IV

Pharmalytik

AAPS_0409: 42

Phase II/III Stability Protocol


Stability profile of clinical materials must be monitored Test stations
25 C/60%RH 30 C/65%RH (if trial conducted in zone III and IV) 40 C/75%RH (Open Dish, 2 wks, 1mo) 40 C/75%RH ICH Photostability (Open Dish & in container)

What packaging will be required


Is your product moisture, light or heat sensitive Desiccant needed/filler
Pharmalytik
AAPS_0409: 43

Phase II Strategies and Goals...


Finalize formulation and process Finalize drug substance process Define market image (Product definition, Packaging) Develop global stability protocol Support clinical trials Prepare for End-of-Phase II meeting

Scale-up/Optimization of process parameters

Enough stability data to support matrixing or bracketing design if desired Microbiology testing needed? Moisture? Chiral purity Stability studies on product made at the extremes of process as defined by experimental design Wet granulation/Compression force On stability one to three months prior to start of Phase III
AAPS_0409: 44

Demo/scale-up batch

Pharmalytik

Phase III Strategies...


Manufacture submission batches (representative of commercial production)
12 month stability by time of filing Cover zone III and IV and Japan

Three batches per strength


2 at least pilot-scale (NLT 10%) - >100,000 units 1 lab-scale (25,000-50,000 units)

In the container and closure proposed for marketing Implement global stability protocol Outsource stability testing if needed Automate as possible Data to support setting specifications
Pharmalytik
AAPS_0409: 45

Typical Phase II/III Stability Protocol


Cond. 25C 60%RH 30C 65%RH (30C 75%RH) 40C 75%RH Photo X X (x) TZ X H O 1mo 2mo 3mo X L X X 6mo X D X X X X X X X 9mo X 12mo X 18mo X 24mo X 36mo (EOS) X

30C/75%RH if clinical study is done in Zone III/IV


Pharmalytik
AAPS_0409: 46

Stability Testing Recommended


1. ICH Photostability: Test 1st lot in open dish. Test immediate package on if significant change. 2. 30C/65%RH : HOLD, to be tested if 40C/75%RH meets ICH significant change criteria. If clinical study is done at Zone 3 or 4, test 30C/65%RH at 9, 12, 24 and 36 or LPO. 4. X-ray powder diffraction: Test 1st lot at 25C/60%RH (TZ, 12, 18, 24 and 36) and 40C/75%RH (6 mo) 5. Chiral assay: Test 1st lot at 25C/60%RH (TZ, 12, 18, 24 and 36)

Pharmalytik

AAPS_0409: 47

Global Protocol NDA/MAA Considerations


Conforms to ICH and regional guidelines, especially storage conditions) Generate data to support registrations worldwide (all 4 climate zones) Global Packaging, Container/closure requirements, including regional specific packages Support registration of drug substance & drug product - Analytical Tests and Global Specifications Ideally, a global stability program for all registrations of a drug product
Pharmalytik
AAPS_0409: 48

Typical NDA/MAA Stability Protocol


Cond. 25 C 60%RH 30 C 65%RH 40 C 75%RH 50 C Photo 5C (X) H O L D TZ X H X O 1mo 2mo 3mo X L X X 6mo X D X 9mo X 12mo X 18mo X 24mo X 36mo X

Pharmalytik

AAPS_0409: 49

Typical Global Protocol (For all 4 zones)


Cond. 25 C 60%RH 30 C 65%RH (30 C 75%RH) 40 C 75%RH 50 C Photo 5C (X) H O L D TZ X (X) (X) X 1mo 2mo 3mo X X X X X 6mo X X X X 9mo X X X 12mo X X X 18mo X X X 24mo X X X 36mo X X X

Handbook of Stability Testing in Pharmaceutical Development: Regulations, Methodologies and Best Practices, K. Huynh-Ba (ed.), Springer, November 2008

Pharmalytik

AAPS_0409: 50

Testing Recommended
ICH Photostability: open dish testing on 1st lot. 5C: Sufficient samples must be placed at this condition to allow for testing at 4 timepoints. 30C/65%RH : HOLD, to be tested if 40C/75%RH meets ICH significant change criteria. X-ray powder diffraction: Test first lot at 25C/60%RH annually and 40C/75%RH (6 mo) Chiral assay: Test first lot at 25C/60% every 6 months Microbial bioburden: test at least one lot at 25C/60%RH (TZ) unless data supports not testing. If moisture is 2 x TZ and water activity is NLT 0.6, test at 25C/60%RH every 6 months For liquid, extractable at TZ and EOS (plastic containers only) when package and label adhesives are defined for the marketed product.
Pharmalytik
AAPS_0409: 51

Special Storage Conditions


Liquids in Semi-Permeable Containers Long-Term: 25oC/405%RH (Zone I/II) or 30oC/355%RH (all zones) Intermediate: 30oC/655%RH Accelerated:
a. b. c.

40oC/NMT25%RH

or 25C/60RH and calculate wt. loss equiv. to 25C/40RH if 30C/35RH is long-term condition, no intermediate condition is needed Test one lot exposed at 40C/NMT 25%RH for aqueous only; not needed for impermeable containers.

Pharmalytik

AAPS_0409: 52

Adverse Shipping Conditions


Thermal Cycling
e.g., 40oC, 4 days, then 25oC/60%RH, 3 days Repeat cycle twice Perform full testing at end of complete cycling Helpful in addressing questions from marketing and sales

Freeze-Thaw Cycling
e.g., -20oC, 4 days then 25oC/60%RH, 3 days Repeat cycle twice Perform full testing at end of complete cycling
Pharmalytik
AAPS_0409: 53

Additional Considerations
Based on developmental info, add time points around expected expiry to improve confidence in shelf-life estimates If time permits, extend studies for longer shelf-life Climatic Zones III & IVa Continue testing at 30oC/65%RH for establishing shelf-life Continue 40oC/75%RH testing to 12 months
Pharmalytik
AAPS_0409: 54

Benefits of Global Stability Program


Improve efficiency All tests are done at the same time All tests are conducted at the same site/lab Good use of testing resources Avoids repeat testing due to regional packages Reduce cycle time Improve consistency Improve quality
Pharmalytik
AAPS_0409: 55

Cycle Diagram
cGMP, ICH, Global Protocols Analytical Methods

SOPs

Stability Program
Data Reports Metrology

Pharmalytik

AAPS_0409: 56

Conclusion
Understand the Regulatory Requirements versus Scientific Requirements Understand stability role in the drug development process Stability profile needs to be established for drug product to assure safety, efficacy and quality. Design strategy for stability study based on data of development batches Need to understand the product to design Formal stability studies Develop stability program and maximize efficiency
Pharmalytik
AAPS_0409: 57

STABILITY NETWORKS
AAPS Stability Focus Group Pharmaceutical Stability Discussion Group Upcoming Meetings:
Stability Workshop, Bethesda, MD Sep. 09 AAPS Annual Meeting, Los Angeles, CA Nov. 09 EAS Annual Meeting, Somerset, NJ Nov. 09

Pharmalytik

AAPS_0409: 58

References

Handbook of Stability Testing in Pharmaceutical Development: Regulations, Methodologies and Best Practices, Kim Huynh-Ba (ed.), Springer Science and Media Publishing, available November 2008, ISBN: 978-0-387-85626-1 Publishing www.springer.com or www.amazon.com
Molzon J. (2007), FDA, Current International Harmonisation Efforts: Opportunities and Challenges - A Regulator's Perspective. Kopp S. (2007), WHO, Update on WHO Guidelines.

Slamet L. (2007), National Agency of Drug and Food Control, Indonesia, Requirements for South East Asian Markets. Saleh A. (2007), WHO EMRO, Regional Guidelines on Stability Testing of API and Pharmaceutical Products for the Eastern Mediterranean Region. Zahn M. et al. (2006), 3RPharma A risk-based approach to establish stability testing conditions for tropical countries, Journal of Pharmaceutical Sciences 95: 946-965 / Erratum 96: 2177 (2007) G. Buehler (2007), FDA OGD, Regulatory Requirements for Stability Testing of Generics. J. Needels & M. Seibel, Novartis & Procter Gamble, Stability Design for Consumer Healthcare Products.

W. Grimm (1987), Stability Testing of Drug Products.

Pharmalytik

AAPS_0409: 59

THANK YOU!!! Any question?

Kim Huynh-Ba PHARMALYTIK Kim.huynhba@pharmalytik.com www.pharmalytik.com

Pharmalytik

AAPS_0409: 60